FDASIA: The Perfect Name for PDUFA V
This article was originally published in RPM Report
The House and Senate negotiators picked the perfect acronym for the newest version of the Prescription Drug User Fee Act: FDASIA – as in FDA/Asia with a dose of Fantasia. On the safety side, the law will help FDA adapt to a global supply chain and especially the rise of China and India. As for accelerating drug development, the fantasy may outpace the reality.
You may also be interested in...
A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.
Final phase overhaul of FDA's new drug review groups includes half-a-dozen first-time division directors. Most have long experience at the agency – but not all with the drugs they will now oversee.
If the President says over and over again that a drug is approved, does that make it so?